In addition to the above efficacy, Tirzepatide has been demonstrated to improve intrahepatic triglycerides in T2D when compared to insulin degludec [52], which may provide new therapeutic strategy for patients with fatty liver as describing for GLP-1 RAs [53]. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.